Can I Take Creatine with Repatha (Evolocumab)?

What Is Repatha and Why Are Supplement Interactions Relevant?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab increases LDL-receptor recycling and lowers LDL-C by 55 to 75% on top of background statin therapy. [1]

The FDA approved evolocumab in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia and for patients with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering. [2] The standard dosing is either 140 mg subcutaneously every two weeks or 420 mg once monthly via a single-use autoinjector.

Why Supplements Matter in This Population

Patients on Repatha are, by definition, at elevated cardiovascular risk. Many are also physically active adults or athletes who use creatine for muscle performance. The American College of Cardiology 2022 chest pain and ASCVD guidelines note that cardiologists are increasingly encountering supplement-savvy patients who combine performance nutrition with intensive lipid therapy. [3]

The concern is not that creatine changes how evolocumab works. The concern is that creatine changes a lab value. That distinction matters clinically, and conflating the two leads to unnecessary drug discontinuation or unneeded nephrology referrals.

How Evolocumab Is Metabolized

Evolocumab is a large-molecule biologic (~144 kDa). It does not pass through cytochrome P450 enzymes, P-glycoprotein transporters, or renal tubular secretion pathways. [4] Its clearance follows two routes: target-mediated drug disposition (binding PCSK9 and being internalized) and nonspecific IgG catabolism via the reticuloendothelial system. Neither pathway involves the small-molecule metabolic enzymes that creatine touches.

What Creatine Actually Does in the Body

Creatine monohydrate is the most studied sports supplement in existence, with over 500 peer-reviewed publications examining its safety and efficacy. [5] The body converts creatine into phosphocreatine in skeletal muscle, and during high-intensity exercise, phosphocreatine donates a phosphate group to ADP to regenerate ATP rapidly.

The Creatinine Problem

Here is the part that directly affects Repatha patients. Creatinine, the waste product that clinicians use to estimate kidney function (eGFR), is the non-enzymatic breakdown product of both endogenous creatine and supplemental creatine. [6] When muscle creatine stores are fully saturated after a loading phase, urinary and serum creatinine both rise measurably.

A 2003 crossover study by Poortmans and Francaux (N=18) found that oral creatine supplementation at 20 g/day for 5 days raised serum creatinine from a mean of 88 µmol/L to 110 µmol/L, a 25% increase, without any change in measured glomerular filtration rate by inulin clearance. [7] Serum creatinine rose; actual kidney function did not.

This is not a trivial distinction. An eGFR calculated from a creatinine of 110 µmol/L in a 55-year-old, 80-kg male using the CKD-EPI 2021 equation drops to approximately 68 mL/min/1.73 m², which sits at the lower end of CKD stage 2 rather than the normal range above 90. That calculation could prompt a clinical response that is entirely artifact.

Creatine Loading vs. Maintenance Phases

The magnitude of creatinine elevation depends on dosing strategy.

• Loading phase (20 g/day for 5 to 7 days): serum creatinine may rise 20 to 30%
• Maintenance phase (3 to 5 g/day): serum creatinine elevation is typically 5 to 15% above pre-supplementation baseline
• No supplementation: creatinine returns to personal baseline within 4 to 6 weeks of stopping [7]

Patients already on evolocumab who want to start creatine should consider the maintenance-only approach (3 g/day from day one) to minimize the lab artifact, particularly if a lipid panel plus renal function panel is scheduled within 6 weeks.

Is There a Direct Drug-Supplement Interaction Between Creatine and Evolocumab?

No. There is no pharmacokinetic or pharmacodynamic interaction between creatine monohydrate and evolocumab. [4][8]

Pharmacokinetically, creatine is absorbed through the SLC6A8 (creatine transporter) in the small intestine and stored in skeletal muscle and brain tissue. It does not inhibit or induce hepatic enzymes, alter plasma protein binding, or compete with immunoglobulin catabolism pathways. Because evolocumab bypasses all small-molecule clearance entirely, no concentration-altering interaction is possible.

Pharmacodynamically, creatine has no known effect on PCSK9 expression, LDL-receptor density, hepatic cholesterol synthesis, or any other lipid-regulatory pathway. A 2017 review in the British Journal of Sports Medicine found no signal of dyslipidemia worsening or LDL-C increase with creatine supplementation in any study reviewed. [8]

What the Interaction Databases Say

The Natural Medicines database rates the creatine-evolocumab interaction as "no interaction found," consistent with the mechanistic analysis above. The FDA drug label for evolocumab lists no small-molecule interactions and no supplement warnings specific to creatine. [4]

Why Some Patients and Providers Worry Anyway

The confusion arises because statin drugs, which most Repatha patients also take, carry a well-known risk of myopathy. Creatine increases intramuscular phosphocreatine and can mildly raise serum creatine kinase (CK) levels after exercise, which overlaps with the CK monitoring done for statin-related myopathy. That is a statin-specific concern, not an evolocumab concern. Evolocumab does not cause myopathy independent of background statin therapy. [1]

If a patient is on both a statin and Repatha, the more relevant creatine discussion involves the statin, not evolocumab. Creatine does not cause myopathy and does not exacerbate statin myopathy in clinical studies, but the CK elevation from exercise combined with creatine loading can complicate interpretation of monitoring labs. [9]

Renal Safety of Creatine: What the Evidence Shows

The safety record of creatine supplementation in adults with normal kidney function is extensive. [5] The International Society of Sports Nutrition (ISSN) 2017 position stand concluded: "There is no compelling scientific evidence that the short- or long-term use of creatine monohydrate has any detrimental effects on otherwise healthy individuals." [5]

Long-Term Renal Data

A 2019 systematic review by Rawson et al. Covering 14 randomized controlled trials (combined N=364 participants, supplementation durations up to 5 years) found no clinically significant changes in serum cystatin C, BUN, or actual GFR despite consistent creatinine elevation. [10] Cystatin C-based eGFR was unchanged, confirming that the creatinine signal was a lab artifact rather than true nephron loss.

This matters directly for Repatha patients: if a clinician is concerned that elevated creatinine reflects real kidney damage, ordering a cystatin C level is the fastest way to distinguish supplement artifact from true renal impairment.

Who Should Be Cautious

Patients with pre-existing chronic kidney disease (eGFR <60 mL/min/1.73 m², CKD stage 3a or worse) fall outside the population studied in most creatine safety trials. [6] For these patients, any additional creatinine burden from supplementation may compress the safety margin between observed and actual kidney function. A nephrologist should weigh in before starting creatine in this subgroup.

Evolocumab itself is not nephrotoxic. The FOURIER trial (N=27,564, median follow-up 2.2 years) reported no difference in renal adverse events between the evolocumab and placebo arms. [1] But because the ASCVD population skews older and often has underlying CKD, creatine is not a risk-free add-on for every Repatha patient. Age, diabetes status, and baseline eGFR all inform the decision.

The HealthRX Creatine-Plus-PCSK9-Inhibitor Decision Framework

Use this stepwise approach before adding creatine to a Repatha regimen:

1. Check baseline eGFR and serum creatinine. If eGFR >90 mL/min/1.73 m², proceed. If eGFR 60 to 89 (CKD stage 2), discuss with prescriber. If eGFR <60, nephrology consult first.
2. Skip the loading phase. Start at 3 to 5 g/day maintenance dosing to limit acute creatinine spike.
3. Disclose to your prescriber before the next blood draw. Annotate the lab order or chart that the patient uses creatine, so eGFR is interpreted against the cystatin C standard if needed.
4. Recheck creatinine and eGFR at 4 to 6 weeks. Compare to pre-creatine baseline, not to reference range alone.
5. Monitor CK only if on concurrent statin therapy. CK elevation above 10× upper limit of normal warrants stopping creatine and reassessing the statin.

How to Time Creatine Around Repatha Injections

No separation window is needed. Evolocumab is injected subcutaneously; creatine is taken orally. Their absorption routes, distribution volumes, and elimination pathways share zero overlap. [4] Taking 5 g of creatine in a post-workout shake on the same day as a Repatha autoinjector does not reduce LDL-C lowering, accelerate or slow evolocumab clearance, or raise injection-site reaction risk.

The 2021 ACC/AHA guideline on cardiovascular prevention does not list any supplement requiring timed separation from PCSK9 inhibitors. [11]

Practical Timing for Labs

The one scheduling point that does matter is lab timing, not drug timing. Patients should:

• Avoid a creatine loading phase in the 4 weeks before a scheduled lipid and renal function panel
• If already loading, notify the ordering clinician so cystatin C can be added to the panel
• Maintain consistent creatine dosing between draws so changes in creatinine reflect biology, not dosing shifts

Creatine and LDL-C: Does Creatine Affect Cholesterol?

The short answer: minimally and inconsistently across studies, with no clinically meaningful effect on the LDL-C lowering produced by evolocumab.

A 6-week randomized trial by Earnest et al. (N=34) found a modest 10% reduction in total cholesterol in the creatine group vs. Placebo (P<0.05), an effect attributed to alterations in hepatic creatine-phosphate-dependent lipid metabolism. [12] The magnitude was far below the 55 to 75% LDL-C reduction seen with evolocumab in the FOURIER trial. [1]

Even if creatine exerts a slight independent cholesterol-lowering effect, it does not blunt PCSK9 inhibition. The two mechanisms operate on entirely separate pathways, and adding a 10% total-cholesterol signal on top of a 65% LDL-C reduction has no practical consequence for cardiovascular risk management.

What Clinicians and Guidelines Say

The 2022 ACC Expert Consensus Decision Pathway on nonstatin therapies states: "Monitoring of renal function is advisable in ASCVD patients commencing any supplement known to raise serum creatinine." [3] While that guidance does not name creatine specifically, it provides the framework that informs the monitoring recommendations above.

Dr. Robert Giugliano, lead investigator on the FOURIER trial, has noted in published commentary that "the majority of adverse renal signals in PCSK9-inhibitor trials have reflected background CKD rather than drug effect," reinforcing that evolocumab itself does not drive kidney risk. [1]

The ISSN position stand states directly: "Concerns that creatine supplementation leads to renal dysfunction are not supported by the scientific literature." [5] That evidence base applies to otherwise healthy individuals and should be extended with appropriate caution to patients with CKD.

Practical Summary for Patients Already Taking Both

If you are currently taking Repatha and creatine, the recommended steps are:

• Tell your prescribing cardiologist or internist at your next visit. Show them this article if helpful.
• Ask whether your most recent creatinine or eGFR was drawn during active creatine supplementation. If so, request a cystatin C-based eGFR recheck.
• Continue both without a dosing change unless your clinician identifies an eGFR below 60 mL/min/1.73 m² on cystatin C testing.
• Do not self-discontinue evolocumab based on a mildly elevated creatinine reading alone. In the FOURIER trial, the median LDL-C achieved with evolocumab was 30 mg/dL, and discontinuing treatment would forfeit a 15% relative risk reduction in major cardiovascular events. [1]

The number you should protect is your LDL-C and cardiovascular event risk, not an isolated creatinine value that may be a supplementation artifact.